‘De-intergration’ of Sandoz from Novartis expected to include manufacturing cuts

‘De-intergration’ of Sandoz from Novartis expected to include manufacturing cuts

Source: 
Fierce Pharma
snippet: 

Novartis had what CEO Vas Narasimhan called a transformative year in manufacturing in 2018 as it closed or sold eight facilities and restructured eight others to be more efficient, moves that led to nearly 2,000 job cuts. But more is in store for manufacturing over the next 18 months as Novartis transforms its generics unit Sandoz into an “autonomous unit within Novartis.”